Log In
BCIQ
Print this Print this
 

Biosimilar pegaspargase (PF-690)

  Manage Alerts
Collapse Summary General Information
Company Strides Arcolab Ltd.
DescriptionBiosimilar of pegaspargase, a pegylated L-asparaginase
Molecular Target
Mechanism of ActionEnzyme replacement therapy; Biosimilar
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL)
Regulatory Designation
PartnerPfenex Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$181.0M

0

$166.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/28/2016

$181.0M

Undisclosed

$166.0M

Get a free BioCentury trial today